Sarm S4 Andarine Yellow powder

Andarine (S-4) is the arylpropionamide-derived compound [S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide] first described by Yin et al. to be a selective androgen receptor modulator (SARM). Andarine (S-4) was shown by in vitro and in vivo studies to be an effective anabolic agonist, without side-effects often associated with anabolic-androgenic steroids, relating principally to substrate affinity for 5α-reductase to produce DHT in the prostate.
The pharmacological activity of andarine suggest the great potential of andarine in the development of the clinically available SARMs, which offers unique therapeutic advantages over their steroidal counterparts and an exciting opportunity to differentially regulate the androgen effects in various target tissues, thus minimizing the interference to normal. Thus, andarine has promising in advanced clinical trials that aim to treat age-related maladies and to counteract symptoms of severe diseases such as sarcopenia and cancer cachexia.
Andarine is a selective nonsteroidal androgen receptor (AR) agonist with Ki of 4 nM. Andarine exhibits potent and efficacious anabolic activity and results in dose-dependent stimulation of growth in prostate, seminal vesicles, respectively. Andarine has potential antiosteoporotic properties.
Andarine (formerly known as GTx-007; S-4; GTx007; S4) is an orally bioactive and selective non-steroidal androgen receptor (AR) agonist, specifically a selective androgen receptor modulator (SARM), that has potential usefulness in muscle wasting and osteoporosis. It activates AR with a Ki of 4 nM and is tissue-selective for anabolic organs. Andarine is being investigated for treating conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects.